Mednax, Inc (MD) Position Held by Bright Rock Capital Management LLC
Bright Rock Capital Management LLC maintained its stake in shares of Mednax, Inc (NYSE:MD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,600 shares of the company’s stock at the end of the second quarter. Bright Rock Capital Management LLC’s holdings in Mednax were worth $1,244,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. First Citizens Bank & Trust Co. purchased a new stake in shares of Mednax during the first quarter worth approximately $357,000. American Capital Management Inc. increased its stake in shares of Mednax by 1.0% in the first quarter. American Capital Management Inc. now owns 294,735 shares of the company’s stock worth $20,449,000 after buying an additional 2,790 shares during the last quarter. GW Henssler & Associates Ltd. increased its stake in shares of Mednax by 12.7% in the first quarter. GW Henssler & Associates Ltd. now owns 152,837 shares of the company’s stock worth $10,604,000 after buying an additional 17,183 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock worth $158,000 after buying an additional 102 shares during the last quarter. Finally, Retirement Systems of Alabama increased its stake in shares of Mednax by 0.9% in the first quarter. Retirement Systems of Alabama now owns 175,089 shares of the company’s stock worth $12,148,000 after buying an additional 1,477 shares during the last quarter.
Mednax, Inc (MD) opened at 42.71 on Thursday. The stock has a market capitalization of $3.94 billion, a PE ratio of 13.60 and a beta of 0.40. The stock’s 50 day moving average is $55.09 and its 200-day moving average is $61.77. Mednax, Inc has a 52 week low of $42.62 and a 52 week high of $72.13.
Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business’s revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm posted $1.03 earnings per share. Equities research analysts forecast that Mednax, Inc will post $3.31 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/mednax-inc-md-position-held-by-bright-rock-capital-management-llc.html.
A number of equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Thursday, April 13th. Jefferies Group LLC restated a “hold” rating and issued a $58.00 price objective on shares of Mednax in a research report on Wednesday, April 26th. Bank of America Corporation downgraded shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. BidaskClub upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $55.00 to $68.00 in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company. Mednax presently has an average rating of “Hold” and a consensus price target of $64.00.
In related news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the sale, the director now directly owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.